Table 1.
Demographic and clinical characteristics of the 764 men included for analysis
| Characteristic | Lethal cases (n = 410) | Indolent cases (n = 354) |
|---|---|---|
| Ancestry group, No. (%) | ||
| African American | 114 (27.8) | 74 (20.9) |
| European American | 296 (72.2) | 280 (79.1) |
| DNA from blood, No. (%) | 405 (98.8) | 345 (97.5) |
| Hospital, No. (%) | ||
| Dana-Farber/Brigham and Women’s Hospital | 348 (84.9) | 306 (86.4) |
| Hospital of the University of Pennsylvania | 5 (1.2) | 9 (2.5) |
| Tulane University | 18 (4.4) | 0 (0.0) |
| Wayne State University | 39 (9.5) | 39 (11.0) |
| Median age at diagnosis (IQR)a, y | 62.7 (57.0, 68.2) | 58.2 (53.5, 63.5) |
| Median age at lethal event (IQR)b, y | 66.9 (59.4, 73.6) | —d |
| M stage at diagnosis, No. (%) | ||
| M0 | 212 (51.7) | 354 (100.0) |
| M1 | 150 (36.6) | 0 (0.0) |
| Unknown | 48 (11.7) | 0 (0.0) |
| T stage at diagnosis, No. (%) | ||
| T1 | 214 (52.2) | 241 (68.1) |
| T2 | 49 (12.0) | 47 (13.3) |
| T3 | 17 (4.1) | 7 (2.0) |
| T4 | 7 (1.7) | 0 (0.0) |
| Unknown | 123 (30.0) | 59 (16.7) |
| Median PSA at diagnosis (IQR)c, ng/mL | 13.5 (6.2, 56.8) | 4.6 (3.6, 5.7) |
| Final Gleason Grade Group, No. (%) | ||
| 1 (Gleason score ≤6) | 31 (7.6) | 340 (96.0) |
| 2 (Gleason score 3 + 4) | 58 (14.1) | 14 (4.0) |
| 3 (Gleason score 4 + 3) | 43 (10.5) | 0 (0.0) |
| 4 (Gleason score 8) | 70 (17.1) | 0 (0.0) |
| 5 (Gleason score 9-10) | 149 (36.3) | 0 (0.0) |
| Unknown | 59 (14.4) | 0 (0.0) |
| Primary treatment, No. (%) | ||
| Radical prostatectomy | 116 (28.3) | 335 (94.6) |
| External beam radiation only | 29 (7.1) | 8 (2.3) |
| External beam radiation with hormones | 55 (13.4) | 0 (0.0) |
| Brachytherapy | 10 (2.4) | 2 (0.6) |
| Active surveillance | 2 (0.5) | 9 (2.5) |
| Hormones alone | 132 (32.2) | 0 (0.0) |
| Other | 49 (12.0) | 0 (0.0) |
| Unknown | 17 (4.1) | 0 (0.0) |
a
Age at diagnosis was missing for 2.9% of lethal cases and 3.4% of indolent cases. IQR = interquartile range; PSA = prostate-specific antigen.
b
Age at lethal disease was missing for 9.3% of lethal cases.
c
PSA at diagnosis was missing for 16.3% of lethal cases and 8.8% of indolent cases.
d
Not applicable.